Stem cell research in the embryonic stage
October 13, 2010 - Proponents of embryonic stem cell research are hailing a new era as Geron has injected its first patient with about 2 million "oligodendrocyte progenitor cells."
Opponents of embryonic stem cell research are, predictably, less than impressed, accusing the company of attempting to boost its stock price.
Some of the nervousness among scientists involves not the predictable reactions of stem cell research foes, but of the unpredictable possible reactions of the public. HealthDay notes: "There's a lot of angst around these trials," Evan Snyder, director of the stem cell program at the Sanford-Burnham Medical Research Institute in San Diego, tells the Washington Post. "There's going to be this perception that if the cells do not perform well, the entire field will be illegitimate."
Read the related article from The Washington Post: First patient treated in stem cell study
Or Bloomburg Businessweek's Healthday: First patient treated in U.S.-approved embryonic stem cell trial